Most men over 45 walking into a TRT clinic think they’re getting a shortcut.
They’re not.
They’re being sold a treatment that — for the average man complaining of low drive or soft erections — works no better than placebo, comes with a 65% higher risk of prostate problems, and can cost them $200 to $400 a month for the rest of their lives.
This isn’t a supplement company saying it. This isn’t a wellness influencer.
This is Cochrane. The gold standard of medical evidence review. The people every medical school on earth trains its students to trust above almost every other source.
In September 2024, they published a systematic review that pooled 43 randomized controlled trials, 11,419 men, and asked one simple question:
Does testosterone replacement therapy actually help men with sexual dysfunction — compared to a placebo?
The answer is going to make a lot of TRT clinics uncomfortable.
Source: https://pubmed.ncbi.nlm.nih.gov/39344112/
What the Cochrane review actually found
43 randomized controlled trials. 11,419 men. Every major TRT study of the last two decades, pooled and analyzed with the strictest evidence methodology in medicine.
The findings, in plain English:
Erectile function: TRT improved erection scores by 2.37 points on the standard 30-point scale (IIEF-EF) versus placebo. Most urologists consider a 4-point change the minimum “clinically meaningful” difference. TRT didn’t get there.
Sexual quality of life: No meaningful difference vs placebo.
Cardiovascular mortality: No meaningful difference vs placebo.
Prostate-related events: 65% higher in the TRT group. Statistically significant. This one wasn’t a wash.
Let that land.
For the average middle-aged man walking into a TRT clinic complaining of low drive, soft erections, or fatigue — testosterone replacement therapy works about as well as a sugar pill, and comes with a measurably higher risk of prostate problems.
Takeaway: The shortcut you’re being sold is not a shortcut. It’s a lifetime prescription with a prostate tax.
The 65% number, explained
Prostate-related events in the Cochrane review included things like:
Elevated PSA (prostate-specific antigen) requiring biopsy
New prostate cancer diagnoses
Benign prostatic hyperplasia (enlarged prostate)
Urinary retention requiring intervention
The risk ratio was 1.65 — meaning TRT users had a 65% higher rate of these events than placebo users across 10 randomized trials with 3,439 participants.
This isn’t a small side effect footnote. This is a statistically significant safety signal that the majority of TRT clinics either downplay, don’t mention, or actively deny.
Ask any TRT clinic advertising to men over 45: “What’s my prostate risk on this treatment?” Most will say “monitored closely, minimal risk.” Cochrane’s data says otherwise.
Takeaway: A 65% increase in prostate events is not a rounding error. It’s the number your clinic should have told you before writing the script.
Why the TRT industry doesn’t want you reading this
The TRT market in the U.S. alone is projected to exceed $2 billion annually. It’s grown 4x in the last decade. Most of that growth isn’t from men with actual hypogonadism (medically diagnosed low testosterone) — it’s from eugonadal men (men with normal testosterone) being sold the treatment through direct-to-consumer clinics.
The Cochrane authors flagged this directly in their paper — they cited concerns about “widespread use of testosterone for eugonadal men based on both global and US data, which reflect an overall increase in the prescribing of TRT, possibly as self-medication in response to advertising.”
Translation: doctors are watching men with normal T get prescribed testosterone because they saw an Instagram ad.
Takeaway: You’re being marketed to. Hard. The evidence doesn’t support the marketing.
The 3 questions to ask before you ever step into a TRT clinic. Who TRT actually works for — and how to know if that’s you. The 4 lifestyle levers that outperformed TRT in multiple head-to-head studies. Plus what to do if you’ve already started TRT and want to know if you should stay on it.
Who TRT actually works for
Let’s be fair. TRT is not a scam. It’s a real medical treatment that works — for the right man.
TRT works well for men with primary or secondary hypogonadism — clinically diagnosed low testosterone confirmed by two morning blood draws, typically with total T under 300 ng/dL and symptoms consistent with actual deficiency (not just fatigue and low libido, which can have dozens of causes).
For those men, TRT can be life-changing. Real energy return, real mood improvement, real muscle preservation, real drive.
The problem isn’t TRT itself. The problem is that most men being prescribed TRT today are not those men.
The Cochrane review specifically excluded men with primary or secondary hypogonadism because they wanted to test the drug on the population that’s actually being sold it in the real world: middle-aged men with sexual symptoms but not diagnosed hormonal deficiency.
Takeaway: TRT for men who genuinely need it: life-changing. TRT for men chasing a shortcut: expensive placebo with a prostate risk.
3 questions to ask before you ever start TRT
What is my total testosterone on two separate morning blood draws, taken between 7 and 10 a.m.? Single tests are unreliable. Testosterone fluctuates. If your clinic prescribes based on one test, walk out.
What is my free testosterone, SHBG, LH, and estradiol? Total T alone doesn’t tell you what’s happening. Free T is what your body can actually use. LH tells you if the problem is your testicles or your pituitary. If your clinic doesn’t run these, they don’t know what they’re treating.
What is my prostate baseline — PSA, DRE, and if indicated, MRI? Given the 65% higher event rate, any competent TRT protocol requires a documented prostate baseline before you inject anything. If your clinic skips this, walk out.
If your clinic can’t answer these three questions in detail, they’re not treating you. They’re selling to you.
Takeaway: Real treatment starts with real diagnostics. Anyone skipping the workup is skipping the medicine.
The 4 lifestyle levers that outperformed TRT in head-to-head studies
Here’s what almost no TRT clinic will tell you: for men whose T is low because of lifestyle — which is most middle-aged men — lifestyle intervention often outperforms TRT in the long run.
1. Weight loss. A landmark presentation at ENDO 2025 showed that men with obesity who lost 10% of body weight moved from 53% having normal T to 77% having normal T — a 24-point jump — without any hormone therapy.
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.